Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Lung cancer.

T L Evans¹, T J Lynch

¹Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.

|October 25, 2001

Summary

This summary is machine-generated.

No single combination therapy is superior for metastatic non-small cell lung cancer (NSCLC). Cisplatin may outperform carboplatin, and platinum doublets offer better survival trends than non-platinum regimens in advanced NSCLC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.

ESMO open·2023

Same author

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

Butyrylcholinesterase: an enzyme antidote for cocaine intoxication.

Addiction biology·2016

Area of Science:

Oncology and Medical Research
Clinical Trials and Treatment Strategies for Lung Cancer

Background:

Evaluation of combination therapies for metastatic non-small cell lung cancer (NSCLC) across multiple randomized trials.
Median survival for advanced NSCLC remains approximately 9 months, highlighting the need for improved treatment strategies.

Framework:

Analysis of data from over 4,000 patients presented at the 37th Annual Meeting of the American Society of Clinical Oncology.
Comparison of different chemotherapy regimens, including platinum-based doublets and novel agents.

Implementation:

TAX326 trial showed cisplatin/docetaxel superior to cisplatin/vinorelbine.
Four cycles of chemotherapy demonstrated equivalent survival benefit to treatment until progression.
Novel agents like ISIS 3521 (antisense oligonucleotide) and OSI-774 (EGFR tyrosine kinase inhibitor) showed promising results in combination or second-line settings.

Related Experiment Videos

Implications:

While a definitive 'best' regimen for advanced NSCLC is not established, cisplatin and platinum doublets appear more effective.
The future of NSCLC therapy likely involves combining novel agents with chemotherapy to improve patient outcomes.
In locally advanced NSCLC, chemotherapy combined with radiation therapy shows significant results, as demonstrated by cisplatin/etoposide with radiation followed by docetaxel.